Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats.
Chemopreventive effects of synthetic and naturally occurring antioxidants on heterocyclic amine (HCA)-induced rat carcinogenesis and mechanisms of inhibition were assessed. In a medium-term liver bioassay, combined treatment with 0.03% 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) and synthetic antioxidants such as 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), BHA, BHT, tert-butylhydroquinone (TBHQ) and propyl gallate, each at a dose of 0.25%, and troglitazone at doses 0.5 and 0.1%, potently inhibited development of glutathione S-transferase placental form (GST-P) positive foci as compared with MeIQx alone values. Of these antioxidants, HTHQ showed the greatest activity. Green tea catechins tended to inhibit GST-P positive foci development, while quercetin, rutin, curcumin, daidzin, ferulic acid and genistin all exerted significant enhancing effects. HTHQ also inhibited 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced colon carcinogenesis in a two stage colon carcinogenesis model using 1,2-dimethylhydrazine (DMH) as an initiator. Immunohistochemically detected PhIP-DNA adduct positive nuclei in the colon induced by continuous oral treatment with 0.02% PhIP for 2 weeks decreased by the combined treatment with 0.5 or 0.125% HTHQ. Methoxyresorfin O-demethylase activity in rat liver microsomes in vitro was clearly inhibited by the addition of HTHQ, BHA, BHT, TBHQ or propyl gallate, with particularly strong inhibition being observed in HTHQ. However, the CYP1A2 level in rat liver increased after oral treatment with HTHQ for 2 weeks. These results indicate that synthetic antioxidants, HTHQ in particular, is a very strong chemopreventor of HCA-induced carcinogenesis. It is suggested that depression of metabolic activation rather than antioxidant activity is responsible for the observed effect. However, other mechanisms, including the effects on phase II enzymes cannot be ruled out.
Hirose
M
M
Division of Pathology, Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan. m-hirose@nihs.go.jp
Takahashi
S
S
Ogawa
K
K
Futakuchi
M
M
Shirai
T
T
Shibutani
M
M
Uneyama
C
C
Toyoda
K
K
Iwata
H
H
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D002273:Carcinogens / Q000633:toxicity*; D002392:Catechin / Q000494:pharmacology* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000139:chemically induced* / Q000517:prevention & control*; D004336:Drug Antagonism; D007093:Imidazoles / Q000633:toxicity*; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000517:prevention & control*; D008297:Male; D011804:Quinolines / Q000633:toxicity*; D051381:Rats; D011916:Rats, Inbred F344; D013634:Tannins / Q000494:pharmacology* / Q000627:therapeutic use
D000975:Antioxidants; D002273:Carcinogens; D007093:Imidazoles; D011804:Quinolines; D013634:Tannins; D002392:Catechin; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; C036989:2-amino-3,4-dimethylimidazo(4,5-f)quinoline